BRCA1 shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc.

Product Specs
ItemBRCA1 shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-29219-SH
Quantity20 µg
TypeshRNA Plasmid
Specieshuman
NCBI Full Gene NameBRCA1 DNA repair associated
NCBI Gene AliasesBRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4, PPP1R53, PSCP, RNF53
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathwayExperimental cell researchNovember 1, 2022Sinha S, Chatterjee S, Paul S, Das B, Dash SR, Das C, Kundu CN.

(2) Profilin-1 regulates DNA replication forks in a context-dependent fashion by interacting with SNF2H and BOD1LNature communicationsNovember 1, 2022Zhu C, Iwase M, Li Z, Wang F, Quinet A, Vindigni A, Shao J.

(3) BRCA1-BARD1 regulates transcription through modulating topoisomerase IIβOpen biologyOctober 1, 2021Bunch H, Jeong J, Kang K, Jo DS, Cong ATQ, Kim D, Kim D, Cho DH, Lee YM, Chen BPC, et al.

(4) Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse modelInternational journal of biological sciencesJanuary 1, 2021Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, et al.

(5) Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer modelsJournal of cellular and molecular medicineSeptember 1, 2020Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG.

(6) Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trialsJournal of cancer research and clinical oncologyMarch 1, 2020Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, et al.

(7) β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissueCarcinogenesisNovember 25, 2019Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.

(8) Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradationCell death and differentiationMay 1, 2019Kim S, Jin H, Seo HR, Lee HJ, Lee YS.control) were purchased from Bioneer (Daejeon, Korea). CTSS sh-RNA plasmid (sc-29941-SH), sh-BRCA1 (sc-29219-SH), and sh-control plasmid (sc-10808) were from Santa Cruz Biotechnology (Dallas, TX, USA), and sh-RNA

(9) Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumorsExperimental & molecular medicineOctober 16, 2018Choi EK, Lim JA, Kim JK, Jang MS, Kim SE, Baek HJ, Park EJ, Kim TH, Deng CX, Wang RH, et al.

(10) Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumorsInternational journal of biological sciencesJanuary 1, 2018Baek HJ, Kim SE, Kim JK, Shin DH, Kim TH, Kim KG, Deng CX, Kim SS.

(11) BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitorsTumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicineOctober 1, 2017Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.

(12) Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signalingBiochemical and biophysical research communicationsOctober 28, 2016Xu X, Lv YG, Yan CY, Yi J, Ling R.

(13) BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cellsOncotargetOctober 20, 2015Ambrosini G, Sawle AD, Musi E, Schwartz GK.

(14) MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1Tumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicineMarch 1, 2015He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H, Zhang X.

(15) Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancyHuman mutationMay 1, 2014Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan YC, Li H, Hu S, Weng Y, Yen Y.

(16) Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARPMolecular medicine (Cambridge, Mass.)September 1, 2011Kim H, Naura AS, Errami Y, Ju J, Boulares AH.

(17) Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approachNutrition and cancerJanuary 1, 2010Satih S, Chalabi N, Rabiau N, Bignon YJ, Bernard-Gallon DJ.

(18) Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent mannerCancer researchAugust 1, 2009Fan S, Meng Q, Saha T, Sarkar FH, Rosen EM.

(19) 6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formationOncogeneMay 31, 2007Yoo YG, Na TY, Yang WK, Kim HJ, Lee IK, Kong G, Chung JH, Lee MO.

(20) Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1Molecular and cellular biologySeptember 1, 2006Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA Jr, McCall W, Sgagias MK, et al.

Be the First to Write a Review!